Sticky cholesterol is an informal name for lipoprotein(a), often written as Lp(a) and pronounced “L-P-little-a.” It’s a type of cholesterol particle that carries an extra protein on its surface, making it cling to artery walls far more easily than regular LDL cholesterol. An estimated 1.4 billion people worldwide have elevated levels, yet most have never been tested for it. Unlike standard cholesterol, Lp(a) levels are almost entirely genetic, meaning diet and exercise have little meaningful effect on them.
What Makes It “Sticky”
Lp(a) starts as a particle very similar to LDL, the form of cholesterol most people know as “bad” cholesterol. What sets it apart is an additional protein called apolipoprotein(a), or apo(a), which is physically attached to the particle’s surface. This protein acts like a sticky patch. Because of it, Lp(a) particles latch onto the walls of arteries more readily than plain LDL particles do, accelerating the buildup of plaque that narrows blood vessels over time.
But the stickiness does more than just trap cholesterol in artery walls. Apo(a) also interferes with your body’s natural clot-dissolving system. Normally, when a small blood clot forms, your body produces enzymes that break it down. Lp(a) competes for the same binding sites on clot fibers that those enzymes need to do their job. The result is that clots persist longer than they should. This two-pronged action, faster plaque buildup plus slower clot removal, is what makes Lp(a) particularly dangerous compared to ordinary LDL.
How It Raises Heart Disease and Stroke Risk
People with Lp(a) at or above 75 mg/dL face an 88% higher risk of cardiovascular disease overall compared to people with low levels. The stroke risk is even more dramatic: more than double the risk, according to data published in the American Heart Association’s journal Circulation. Even smaller elevations matter. For every 25 mg/dL increase in Lp(a), the risk of a cardiovascular event rises by about 23%, and stroke risk specifically climbs by 33%.
These numbers are striking because many people with high Lp(a) have perfectly normal standard cholesterol panels. Their LDL, HDL, and triglycerides may all look fine, giving a false sense of security. Lp(a) operates as a separate, independent risk factor that standard lipid tests don’t capture unless your doctor specifically orders it.
Why It’s Almost Entirely Genetic
More than 90% of the variation in Lp(a) levels between people comes down to a single gene called LPA, located on chromosome 6. Each person inherits one copy from each parent, and the versions you receive largely determine whether your Lp(a) will be low, moderate, or high for your entire life. Age, sex, physical activity, diet, and nutrition do not significantly change your levels.
This is a sharp contrast with standard LDL cholesterol, which responds to diet changes, weight loss, and medications. With Lp(a), you’re essentially born with a set point. That genetic nature is also why testing is particularly important if a close family member has had early heart disease or has been found to have elevated Lp(a). The trait runs strongly in families, with more than 80% of people carrying two differently sized versions of the apo(a) protein, one from each parent.
Who Should Get Tested
The threshold for “high” Lp(a) is generally set at greater than 50 mg/dL (or 125 nmol/L). Between 10% and 30% of the global population exceeds this cutoff, making it more common than diabetes. Despite that prevalence, Lp(a) is not part of routine cholesterol screening in most countries.
Current guidelines from the National Lipid Association recommend testing if you have:
- A personal or family history of early heart disease (heart attack or stroke before age 55 in men or 65 in women)
- Very high LDL cholesterol (above 190 mg/dL) or suspected familial hypercholesterolemia
- A family member with known elevated Lp(a)
- A poor response to statin therapy (less than 20% LDL reduction on a moderate or high dose)
- Calcified aortic valve disease diagnosed before age 65
Because Lp(a) levels are genetically fixed, you typically only need to be tested once. The result won’t change much over your lifetime. If you’ve never had it measured, a single blood draw can tell you where you stand.
Why Standard Treatments Don’t Work
Statins, the most widely prescribed cholesterol drugs, do not lower Lp(a). In fact, a large meta-analysis found that statins actually raise Lp(a) levels by roughly 9% to 24%, depending on the specific drug and dose. This doesn’t mean statins are harmful for people with high Lp(a). They still reduce standard LDL and overall cardiovascular risk. But they don’t address the sticky cholesterol problem.
PCSK9 inhibitors, a newer class of injectable cholesterol medications, offer a modest benefit. They lower Lp(a) by about 20% to 25%, which translates to a reduction of around 10 mg/dL in people with meaningfully elevated levels. That’s helpful but often not enough to bring very high Lp(a) into a safe range.
Diet and exercise, while essential for overall heart health, have no proven ability to reduce Lp(a) in a clinically significant way. This is one of the most frustrating aspects of the condition: someone can do everything “right” and still carry elevated risk because of their genetics.
New Drugs in Development
A new generation of therapies designed specifically to lower Lp(a) production in the liver is now in advanced clinical trials. These drugs work by intercepting the genetic instructions your liver uses to manufacture apo(a), effectively shutting down production of the sticky protein at its source.
The results so far have been dramatic. In phase 2 trials, one drug called olpasiran reduced Lp(a) by up to 97% at certain doses. Another candidate, zerlasiran, achieved reductions greater than 80% with injections given just twice a year. Lepodisiran, a third option, lowered levels by up to 94% in pooled trial data. Pelacarsen, which uses a slightly different mechanism, reduced Lp(a) by up to 80% with weekly injections.
All four drugs are now in large phase 3 trials designed to answer the critical remaining question: does dramatically lowering Lp(a) actually prevent heart attacks and strokes? Results from the first of these trials are expected in 2026. If the outcomes are positive, these drugs could become the first targeted treatments for the estimated 1.4 billion people worldwide with elevated sticky cholesterol.
What You Can Do Now
If you have high Lp(a), the focus shifts to aggressively managing every other risk factor you can control. That means keeping standard LDL cholesterol as low as possible, maintaining healthy blood pressure, not smoking, staying physically active, and managing blood sugar. None of these will lower your Lp(a) directly, but they reduce the total burden on your arteries and lower the chance that elevated Lp(a) leads to a cardiovascular event.
Your doctor may also consider more aggressive LDL-lowering treatment than your standard cholesterol numbers alone would warrant, since high Lp(a) effectively adds hidden risk that traditional risk calculators don’t fully account for. For people at the highest Lp(a) levels, PCSK9 inhibitors may be discussed for their partial Lp(a)-lowering benefit alongside their LDL reduction.